US Patent Issued to Clexio Biosciences on Nov. 25 for "Dosage regime with esketamine for treating neuropsychiatric or neurological conditions" (Israeli Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,478,592, issued on Nov. 25, was assigned to Clexio Biosciences Ltd. (Yokne'am, Israel).

"Dosage regime with esketamine for treating neuropsychiatric or neurological conditions" was invented by Ari Gershon (Jerusalem) and David Dangoor (Jerusalem).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a method for safe and efficacious administration of esketamine."

The patent was filed on Dec. 29, 2020, under Application No. 17/789,648.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=5...